PharmaMar , a través de Pascal Besman , dará a conocer los planes de la compañía .

Pascal Besman, Director de Operaciones de PharmaMar USA, explicará los planes de la compañía durante su presentación el día 10 de abril a las 3:00 p.m CET.

Yondelis Ovario Alemania . Publican los Resultados de Clinica Observational . Conclusión : Yondelis es Efectivo en el Tratamiento de Cáncer de Ovario consiguiendo Respuestas Totales en el 6,5 % de las Pacientes .

Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) For Patients with Platinum-Sensitive Recurrent Ovarian Cancer : A Prospective, Observational, Multicenter Study.

First Online: 06 April 2018

Runnebaum IB, et al. J Cancer Res Clin Oncol. 2018.

Abstract

PURPOSE: The OVA-YOND study is the first prospective, non-interventional trial designed to evaluate trabectedin (1.1 mg/m2) plus PLD (30 mg/m2) in patients with platinum-sensitive recurrent ovarian cancer (ROC), given according to the marketing authorization in real-life clinical practice across Germany.

METHODS: Eligible patients were adults with platinum-sensitive ROC, pretreated with ≥ 1 platinum-containing regimen/s. The primary endpoint was to assess safety/tolerability of the combination.

RESULTS: Seventy-seven patients with platinum-sensitive relapse from 31 sites were evaluated. Patients received a median of 6 cycles (range 1-21) with 39 patients (50.6%) receiving ≥ 6 cycles. Median treatment duration was 4.2 months (range 0.7-18.8), mostly on an outpatient basis (88.3% of patients). Most common grade 3/4 trabectedin-related adverse events (AEs) were leukopenia (18.2%), neutropenia (15.6%), thrombocytopenia (9.1%), alanine (7.8%) and aspartate aminotransferase (6.5%) increase, and nausea/vomiting (5.2% each). Neutropenia (18.2%), leukopenia (15.6%), thrombocytopenia (10.4%), and nausea/vomiting (5.2% each) were the most frequent grade 3/4 PLD-related AEs. 

No deaths attributed to drug-related AEs or unexpected AEs occurred.

 Five patients (6.5%) had a complete response and 19 patients (24.7%) achieved a partial response for an objective response rate of 31.2% with median response duration of 6.25 months. Sixteen patients (20.8%) had disease stabilization for a disease control rate of 51.9%. 

Median progression-free survival was 6.3 months and median overall survival was 16.4 months.

CONCLUSION: Trabectedin plus PLD confer clinically meaningful benefit to pre-treated patients with platinum-sensitive ROC, being comparable to those previously observed in selected populations from clinical trials and with a manageable safety profile.

Seattle Genetics . Presentación en la Conference Antobody Drug Conjugates . 9 - 10 April 2018 .

DESIGN PRINCIPLES FOR MAXIMIZING THE DRUG DELIVERY EFFICIENCY AND THERAPEUTIC INDEX OF ADCS

Robert Lyon, Senior Director Protein Sciences, Seattle Genetics Ltd.

The conjugation of drug-linkers to an antibody can result in increased nonspecific uptake and catabolism in healthy tissues.

This phenomenon has two potential negative consequences—unintended delivery of the drug to non-target tissues, and diminished exposure of the tumor to the ADC.

Careful design of the drug-linker can minimize this effect in preclinical models, with demonstrable decreases in drug concentrations in normal tissues paired with maximal delivery to the tumor.

Toxicology and xenograft studies indicate that the optimized design both decreases off-target toxicity and improves antitumor activity, and we are currently planning to evaluate this design clinically with an anti-CD48 antibody for patients with multiple myeloma.

*********************************

CONFERENCE OVERVIEW

SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018. The Antibody-drug Conjugates market is expected to reach USD 30 Billion by 2023*. http://bit.ly/2hxLtOS

Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.

Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.

Hear from some of the best minds in the industry and partake in valuable discussion with key leaders within the field at this topical and timely event!